Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Fineline Cube Apr 28, 2026
Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Fineline Cube Apr 28, 2026
Company Drug

Easton Pharmaceutical Secures NMPA Approval for Generic Jakavi and Urocit-K

Fineline Cube Nov 22, 2024

Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced that it has received separate marketing...

Company Drug

Innorna’s mRNA Drug IN015 Earns Orphan Drug Designation for PFIC Treatment

Fineline Cube Nov 22, 2024

Shenzhen-based Innorna Co., Ltd, a leading platform company specializing in mRNA technology and LNP (lipid...

Company Deals

Kura Oncology and Kyowa Kirin Ink Licensing Deal for Menin Inhibitor Ziftomenib

Fineline Cube Nov 22, 2024

US-based Kura Oncology, Inc. (NASDAQ: KURA) has entered into a licensing deal with Japan-headquartered Kyowa...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for HRS-6208 Solid Tumor Clinical Study

Fineline Cube Nov 22, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...

Company Deals

CR Pharma’s CR Sanjiu to Sell 51% Stake in Shenghuo for RMB 1.791 Billion

Fineline Cube Nov 22, 2024

China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has announced a significant internal restructuring within...

Company Drug

InxMed’s Ifebemtinib Earns Breakthrough Therapy Designation for NSCLC Treatment in China

Fineline Cube Nov 22, 2024

China-based InxMed (Nanjing) Co., Ltd has announced that the Center for Drug Evaluation of the...

Company Deals

Novartis Expands Gene Therapy Portfolio with Acquisition of Kate Therapeutics

Fineline Cube Nov 22, 2024

Swiss pharmaceutical company Novartis (NYSE: NVS) has announced the acquisition of US-based Kate Therapeutics, Inc.,...

Company Deals Drug

Hua Medicine and Bayer AG Terminate Co-promotion Agreement for HuaTangNing

Fineline Cube Nov 22, 2024

China-based Hua Medicine (HKG: 2552) has announced the termination of its co-promotion agreement with German...

Company Medical Device

United Imaging Installs AI-Powered uMR OMEGA at XRANM’s Breast Health Center

Fineline Cube Nov 22, 2024

Shanghai-based United Imaging Healthcare Co., Ltd. has announced the installation of an ultra-wide-bore AI-empowered uMR...

Company Drug

Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA

Fineline Cube Nov 21, 2024

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced the submission of a New Drug Application...

Company Deals

Sihuan Pharmaceutical’s Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China

Fineline Cube Nov 21, 2024

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced an exclusive licensing agreement between...

Company Drug

Innovent Biologics’ IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment

Fineline Cube Nov 21, 2024

The Center for Drug Evaluation (CDE) website has indicated that China-based Innovent Biologics, Inc. (HKG:...

Company Drug

CDE Includes Double-Crane’s Hydroxocobalamine and Sanofi Genzyme’s Fitusiran in Rare Disease Care Plan

Fineline Cube Nov 21, 2024

China’s Center for Drug Evaluation (CDE) has announced the inclusion of China Resources Double-Crane Pharmaceutical...

Company Drug

Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency

Fineline Cube Nov 21, 2024

Apeiron Therapeutics, a biomarker-driven cancer therapy developer with operations in Shanghai, China, and San Francisco,...

Company Deals

BI Partners with Sinopharm for Promotion of Sifrol and Pradaxa in China

Fineline Cube Nov 21, 2024

German pharmaceutical major Boehringer Ingelheim (BI) has entered into a partnership with China-based Sinopharm Group...

Company Medical Device

Medtronic Receives US Approval for InPen App with Missed Meal Dose Detection

Fineline Cube Nov 21, 2024

US-Irish firm Medtronic (NYSE: MDT) has announced US market approval for its new InPen app,...

Company Deals

CStone Pharmaceuticals Partners with Pharmalink for Suemalimab Commercialization in MENA and South Africa

Fineline Cube Nov 21, 2024

China-based CStone Pharmaceuticals (HKG: 2616) has announced a strategic commercial collaboration with Pharmalink Store –...

Company Drug

NMPA Approves Alpha Biopharma’s Zorifertinib for First-Line NSCLC Treatment with CNS Metastases

Fineline Cube Nov 21, 2024

The National Medical Products Administration (NMPA) has granted approval to China-based Alpha Biopharma’s zorifertinib, commercially...

Company Drug

Pfizer’s Hympavzi Receives European Commission Approval for Hemophilia A and B

Fineline Cube Nov 21, 2024

US pharmaceutical major Pfizer Inc. (NYSE: PFE) has announced that the European Commission (EC) has...

Company Drug

Guangdong Zhongsheng Pharmaceutical’s RAY1225 Shows Positive Results in Phase II Study

Fineline Cube Nov 21, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced positive top-line...

Posts pagination

1 … 254 255 256 … 658

Recent updates

  • Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform
  • Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise
  • AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise
  • GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development
  • Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Company Drug

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

Company Drug

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.